NCT06982534

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

Conditions

• Systemic Sclerosis (SSc)

Interventions

Type	Name	Description
BIOLOGICAL	UTAA91 injection	CAR-modified gamma delta T cells

Timeline

• Start date: 2025-06-01
• Primary completion: 2027-12-01
• Completion: 2040-01-01
• First posted: 2025-05-21
• Last updated: 2025-05-21

Locations

1 site across 1 country: China